The Native Antigen Company expands its range of Omicron anti

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

Related Keywords

, Antigen Company , From The Native Antigen Companynov , Native Antigen Company , C Terminal His Tag , Omicron Spike , Commercial Director , Native Antigen , Antigen , Micron , Antibodies , Clinical Diagnostics , Iagnostics , N Vitro , Infectious Diseases , Eagents , Eceptor , Research , Cars , Ars Cov 2 , Herapeutics ,